Alira Health announces its role as exclusive strategic advisor to AGC Biologics in its acquisition of MolMed SpA.

Drawing on CDMO and biomedical expertise, Alira Health helped AGC Biologics become one of the few companies offering both plasmid production and cell and gene therapy services.

FRAMINGHAM, MA, USA – August 20, 2020 – Alira Health (, an international healthcare and life sciences advisory firm, announced its role as strategic advisor to AGC Biologics, a leading global biopharmaceutical contract development, and manufacturing organization, in their acquisition of MolMed SpA on July 31, 2020. MolMed is an Italian biotechnology company focused on research, development, production, and clinical validation of cell and gene therapies for the treatment of cancer and rare diseases. With this acquisition valued in excess of €220 million, AGC Biologics becomes one of the few CDMO’s offering both plasmid production and end-to-end cell and gene therapy services.

“The acquisition of MolMed is an excellent addition to the service portfolio of AGC Biologics and addresses the growing market for gene and cell therapy,” said Dr. Peter Heinrich, Senior Partner and co-head of this transaction. “Our close partnership with Patricio Massera, CEO of AGC Biologics, and with Carlo Incerti, Chairman of MolMed, helped us bring this transaction to a successful conclusion in a time of great uncertainty and challenge. The Alira Health team is proud to have played a key role in uniting these two innovative organizations.”

“While we work hard to take care of each other and our customers during this very challenging and uncertain time, it’s also important that we ensure the continued growth of our company. AGC Biologics is committed to continuously expanding our offerings and growing our capacity to serve all the needs of current and future customers,” said AGC Biologics CEO Patricio Massera. “We are very pleased to be adding MolMed and its great cell and gene therapy capabilities and track record to AGC Biologics’ global CDMO service offerings.”

“Our unique knowledge of the gene and cell therapy industry and deep understanding of the CDMO business, combined with our expertise in transaction advisory, was a major factor helping in efficiently supporting the roll-out of the transaction as a strategic advisor,” said Benjamin Chambon, Executive Vice President, Transaction Advisory at Alira Health.

“At Alira Health, we work closely with our clients to define and implement growth strategies and wish AGC Biologics continued success as they continue to evolve their service offerings,” added Dr. Martin Pöhlchen, Senior Partner and co-head of this transaction.

About Alira Health:

Alira Health is an international advisory firm on the frontlines of healthcare transformation. We provide a suite of integrated services designed to help healthcare and life science companies innovate and grow across their solutions lifecycle.

Alira Health was founded in 1999 and is based outside of Boston, MA, U.S. It has offices in San Francisco, CA, U.S.; Paris, France; Barcelona, Spain; Munich, Germany; Milan, Italy; and Basel and Geneva, Switzerland. Learn more at

About AGC Biologics:

AGC Biologics is a leading global Contract Development and Manufacturing Organization (CDMO) with a strong commitment to deliver the highest standard of service to clients and partners. The company currently employs more than 1,000 employees worldwide. AGC Biologics’ global network spans three continents, with cGMP-compliant facilities in Seattle, Washington; Boulder, Colorado; Copenhagen, Denmark; Heidelberg, Germany; and Chiba, Japan.

AGC Biologics offers deep industry expertise and unique customized services for the scale-up and cGMP manufacture of protein-based therapeutics, from pre-clinical to commercial mammalian and microbial production. Integrated service offerings include plasmid (GMP pDNA) manufacturing, cell line development, bioprocess development, formulation, analytical testing, antibody drug development and conjugation, cell banking and storage, and protein expression, including the proprietary CHEF1 Expression System for mammalian production. Learn more at

About MolMed:

MolMed is a biotechnology company focused on research, development, production, and clinical validation of gene and cell therapies for the treatment of cancer and rare diseases. Thanks to the experience and know-how acquired in over 20 years of activity, MolMed is a reference player in the Cell & Gene sector, able to manage all phases of research up to the commercialization of advanced gene and cell therapies. Learn more at